The authors searched three databases and included randomized trials evaluating natural or synthetic cannabinoids for MS-related spasticity. Twenty-seven studies with more than 3,000 participants entered the qualitative synthesis.

The interventions were not interchangeable. They included THC:CBD extracts, other cannabis extracts, isolated cannabinoids, synthetic cannabinoids, and smoked cannabis.

In the seven-study pairwise analysis, THC:CBD extracts reduced patient-reported spasticity versus placebo by a mean difference of 0.82 points in the favorable direction. The 95% confidence interval ranged from 0.40 to 1.24 points.

The Bayesian network analysis also favored THC:CBD extracts, with a mean difference of 0.80 points. These estimates indicate a modest average effect, not elimination of spasticity.

Spasticity has both experienced and examiner-measured dimensions. A person may notice less tightness, fewer spasms, or easier daily activity even when an objective scale changes little.

That difference can be clinically meaningful, but it also makes blinding, expectations, scale selection, and the minimum important change especially relevant when interpreting cannabinoid trials.

Adverse events were frequent, although most were described as mild to moderate and serious events were rare. The abstract does not provide product-specific event rates, so the review should not be used to claim that every formulation has the same safety profile.

Sedation, dizziness, cognitive effects, balance, driving, falls, medication interactions, dose, THC exposure, and individual vulnerability remain practical monitoring considerations.

The authors describe cannabinoids as a cautious adjunctive option, not a replacement for established spasticity management. A clinical discussion should define the target symptom, prior treatments, formulation, dose, expected time course, and stopping criteria.

Monitoring should ask whether any subjective improvement produces meaningful gains in function, sleep, comfort, or care burden without unacceptable adverse effects.

Earlier reviews have also suggested modest cannabinoid effects for MS spasticity, but conclusions vary with included trials, formulations, outcome scales, and duration. This review adds a new 27-trial randomized synthesis and network comparison while retaining a low-certainty conclusion.

The next useful evidence would link standardized formulations and doses to patient-important outcomes such as mobility, transfers, sleep, pain, caregiver burden, falls, cognition, and durable treatment continuation.

This review supports a careful therapeutic trial for selected patients more than it supports a broad declaration that cannabinoids treat MS spasticity.

The clinical question is whether a defined product at a defined dose improves a defined patient goal enough to justify adverse effects and complexity. Subjective relief matters, but it should be connected to function and monitored over time.

A Four-Step Reading Frame